OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001346830

Tvardi Therapeutics, Inc. (TVRD)

Tvardi Therapeutics, Inc. (CIK 0001346830, ticker TVRD) reported revenue of $7.14 million ($7,137,000) for FY2024 (2024-01-01 to 2024-12-31) and net income of -$18.21 million (-$18,214,000) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2025-03-11 (accession 0001558370-25-002705) and its 10-K filed 2026-03-31 (accession 0001104659-26-037729).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001346830
TickersTVRD (Nasdaq)
EINnot in EDGAR (or not a valid EIN)
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_1s7chse1fyz55d9kykj8n7zd6m
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$7,137,000FY20242024-01-01 to 2024-12-3110-K2025-03-110001558370-25-002705RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$18,214,000FY20252025-01-01 to 2025-12-3110-K2026-03-310001104659-26-037729NetIncomeLoss
Total assets$32,073,000FY2025as of 2025-12-3110-K2026-03-310001104659-26-037729Assets
Total liabilities$11,127,000FY2025as of 2025-12-3110-K2026-03-310001104659-26-037729Liabilities
Stockholders' equity$20,946,000FY2025as of 2025-12-3110-K2026-03-310001104659-26-037729StockholdersEquity
Operating cash flow-$23,499,000FY20252025-01-01 to 2025-12-3110-K2026-03-310001104659-26-037729NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$3.26 per shareFY20252025-01-01 to 2025-12-3110-K2026-03-310001104659-26-037729EarningsPerShareDiluted
Shares outstanding9,381,344 sharesFY2025as of 2026-03-2610-K2026-03-310001104659-26-037729EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20242024-01-01 to 2024-12-31$7,137,00010-K2025-03-110001558370-25-002705
RevenueFY20232023-01-01 to 2023-12-31$20,968,00010-K2025-03-110001558370-25-002705
RevenueFY20222022-01-01 to 2022-12-31$41,867,00010-K2025-03-110001558370-25-002705
RevenueFY20212021-01-01 to 2021-12-31$23,028,00010-K2024-03-060001558370-24-002609
RevenueFY20202020-01-01 to 2020-12-31$135,082,00010-K2023-03-060001558370-23-002913
RevenueFY20192019-01-01 to 2019-12-31$19,886,00010-K2022-03-010001558370-22-002555
RevenueFY20182018-01-01 to 2018-12-31$13,469,00010-K2021-02-250001558370-21-001839
RevenueFY20172017-01-01 to 2017-12-31$911,00010-K2018-03-150001564590-18-005879
RevenueFY20162016-01-01 to 2016-12-31$86,00010-K2018-03-150001564590-18-005879
Net incomeFY20252025-01-01 to 2025-12-31-$18,214,00010-K2026-03-310001104659-26-037729
Net incomeFY20242024-01-01 to 2024-12-31-$29,397,00010-K2026-03-310001104659-26-037729
Net incomeFY20232023-01-01 to 2023-12-31-$118,513,00010-K2025-03-110001558370-25-002705
Net incomeFY20222022-01-01 to 2022-12-31-$85,474,00010-K2025-03-110001558370-25-002705
Net incomeFY20212021-01-01 to 2021-12-31-$88,441,00010-K2024-03-060001558370-24-002609
Net incomeFY20202020-01-01 to 2020-12-31$8,410,00010-K2023-03-060001558370-23-002913
Net incomeFY20192019-01-01 to 2019-12-31-$106,373,00010-K2022-03-010001558370-22-002555
Net incomeFY20182018-01-01 to 2018-12-31-$74,013,00010-K2021-02-250001558370-21-001839
Net incomeFY20172017-01-01 to 2017-12-31-$58,125,00010-K2020-02-270001558370-20-001659
Net incomeFY20162016-01-01 to 2016-12-31-$57,280,00010-K2019-03-120001564590-19-007389
  • Net income for FY2024 was restated: first reported as -$70,867,000 (accession 0001558370-25-002705, filed 2025-03-11).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-08-142026-06-300001104659-26-096424tvrd-20260630x10q.htm
10-Q2026-05-082026-03-310001104659-26-057528tvrd-20260331x10q.htm
10-K2026-03-312025-12-310001104659-26-037729tvrd-20251231x10k.htm
10-Q2025-11-132025-09-300001104659-25-111289tvrd-20250930x10q.htm
10-Q2025-08-142025-06-300001558370-25-011562tvrd-20250630x10q.htm
10-Q2025-05-132025-03-310001558370-25-007575tvrd-20250331x10q.htm
10-K2025-03-112024-12-310001558370-25-002705cara-20241231x10k.htm
10-Q2024-11-142024-09-300001558370-24-015713cara-20240930x10q.htm
10-Q2024-08-142024-06-300001558370-24-012231cara-20240630x10q.htm
10-Q2024-05-132024-03-310001558370-24-007964cara-20240331x10q.htm
10-K2024-03-062023-12-310001558370-24-002609cara-20231231x10k.htm
10-Q2023-11-132023-09-300001558370-23-018837cara-20230930x10q.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001346830published by the sourcedata.sec.gov/submissions/CIK0001346830.json2026-10-21

Former names

NameFromTo
Cara Therapeutics, Inc.2013-10-042025-04-11
Cara Therapeutics Inc2005-12-062010-07-21

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001346830.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001346830.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001346830" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001346830/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001346830/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1346830"}

On SEC EDGAR

About this data